MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Du, Cheng ^a,b   Yi, Xiaomin ^b,c   Liu, Wenchao ^b   Han, Tao ^a   Liu, Zhaozhe ^a   Ding, Zhenyu ^a   Zheng, Zhendong ^a   Piao, Ying ^a   Yuan, Jianlin ^b   Han, Yaling ^a   Xie, Manjiang ^d   Xie, Xiaodong ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c The 105th Hospital of PLA   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Drug resistance; Human epidermal growth factor receptor 2 (HER2); Metadherin (MTDH); Nuclear factor kappa B (NF B); Phosphatase and tensin homologue deleted from chromosome 10 (PTEN); Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METADHERIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRASTUZUMAB; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC MANIPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

EID: 84928738349     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-869     Document Type: Article

References (50)

1. Tsang RY, Finn RS: Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 2012, 106(1):6-13.
2. Moasser MM: The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26(45):6469-6487.
3. Ayyappan S, Prabhakar D, Sharma N: Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer. Anticancer Res 2013, 33(10):4139-4155.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
5. Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart MJ: Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol 2013, 24(2):273-282.
6. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1):39-51.
7. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008, 26(10):1642-1649.
8. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
9. Nahta R, Esteva FJ: HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006, 8(6):215.
10. Mohd Sharial MS, Crown J, Hennessy BT: Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 2012, 23(12):3007-3016.
11. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L: Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012, 9(1):16-32.
12. Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, Volsky DJ, Fisher PB: Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene 2002, 21(22):3592-3602.
13. Blanco MA, Aleckovic M, Hua Y, Li T, Wei Y, Xu Z, Cristea IM, Kang Y: Identification of staphylococcal nuclease domain-containing 1 (SND1) as a Metadherin-interacting protein with metastasis-promoting functions. J Biol Chem 2011, 286(22):19982-19992.
14. Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ, Fisher PB: Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene 2005, 353(1):8-15.
15. Lee SG, Kang DC, DeSalle R, Sarkar D, Fisher PB: AEG-1/MTDH/LYRIC, the beginning: initial cloning, structure, expression profile, and regulation of expression. Adv Cancer Res 2013, 120:1-38.
16. Yoo BK, Emdad L, Lee SG, Su ZZ, Santhekadur P, Chen D, Gredler R, Fisher PB, Sarkar D: Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology. Pharmacol Ther 2011, 130(1):1-8.
17. Liu HY, Liu CX, Han B, Zhang XY, Sun RP: AEG-1 is associated with clinical outcome in neuroblastoma patients. Cancer Biomark 2012, 11(2-3):115-121.
18. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Place RF, Pookot D, Majid S, Igawa M, Dahiya R: Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene 2007, 26(55):7647-7655.
19. Tokunaga E, Nakashima Y, Yamashita N, Hisamatsu Y, Okada S, Akiyoshi S, Aishima S, Kitao H, Morita M, Maehara Y: Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer. Breast Cancer 2014, 21(3):341-349.
20. Meng X, Brachova P, Yang S, Xiong Z, Zhang Y, Thiel KW, Leslie KK: Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment. PLoS One 2011, 6(6):e20920.
21. Meng X, Thiel KW, Leslie KK: Drug resistance mediated by AEG-1/MTDH/LYRIC. Adv Cancer Res 2013, 120:135-157.
22. Heo J, Lim CK, Whang DR, Shin J, Jeong SY, Park SY, Kwon IC, Kim S: Selfdeprotonation and colorization of 1, 3-bis(dicyanomethylidene)indan in polar media: a facile route to a minimal polymethine dye for NIR fluorescence imaging. Chemistry 2012, 18(28):8699-8704.
23. Wan L, Kang Y: Pleiotropic roles of AEG-1/MTDH/LYRIC in breast cancer. Adv Cancer Res 2013, 120:113-134.
24. Emdad L, Das SK, Dasgupta S, Hu B, Sarkar D, Fisher PB: AEG-1/MTDH/LYRIC: signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis. Adv Cancer Res 2013, 120:75-111.
25. Moelans CB, van der Groep P, Hoefnagel LD, van de Vijver MJ, Wesseling P, Wesseling J, van der Wall E, van Diest PJ: Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. Cancer Lett 2014, 344(1):138-146.
26. Yi X, Zhang G, Yuan J: Renoprotective role of fenoldopam pretreatment through hypoxia-inducible factor-1alpha and heme oxygenase-1 expressions in rat kidney transplantation. Transplant Proc 2013, 45(2):517-522.
27. Li J, Zhang N, Song LB, Liao WT, Jiang LL, Gong LY, Wu J, Yuan J, Zhang HZ, Zeng MS, Li M: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res 2008, 14(11):3319-3326.
28. Yoo BK, Gredler R, Vozhilla N, Su ZZ, Chen D, Forcier T, Shah K, Saxena U, Hansen U, Fisher PB, Sarkar D: Identification of genes conferring resistance to 5-fluorouracil. Proc Natl Acad Sci U S A 2009, 106(31):12938-12943.
29. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y: MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009, 15(1):9-20.
30. Zhang N, Wang X, Huo Q, Li X, Wang H, Schneider P, Hu G, Yang Q: The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer. J Biol Chem 2013, 288(13):9396-9407.
31. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E: Upregulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011, 286(21):19127-19137.
32. De P, Hasmann M, Leyland-Jones B: Molecular determinants of trastuzumab efficacy: What is their clinical relevance? Cancer Treat Rev 2013, 39(8):925-934.
33. Kumler I, Tuxen MK, Nielsen DL: A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 2014, 40(2):259-270.
34. Su P, Zhang Q, Yang Q: Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue. Diagn Pathol 2010, 5:38.
35. Li C, Li R, Song H, Wang D, Feng T, Yu X, Zhao Y, Liu J, Yu X, Wang Y, Geng J: Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathological characteristics in triple-negative breast cancer. J Surg Oncol 2011, 103(2):184-192.
36. Li J, Yang L, Song L, Xiong H, Wang L, Yan X, Yuan J, Wu J, Li M: Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1. Oncogene 2009, 28(36):3188-3196.
37. Sarkar D, Fisher PB: AEG-1/MTDH/LYRIC: clinical significance. Adv Cancer Res 2013, 120:39-74.
38. Emdad L, Lee SG, Su ZZ, Jeon HY, Boukerche H, Sarkar D, Fisher PB: Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc Natl Acad Sci U S A 2009, 106(50):21300-21305.
39. Ward A, Balwierz A, Zhang JD, Kublbeck M, Pawitan Y, Hielscher T, Wiemann S, Sahin O: Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013, 32(9):1173-1182.
40. Garcia-Garcia C, Ibrahim YH, Serra V, Calvo MT, Guzman M, Grueso J, Aura C, Perez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M: Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 2012, 18(9):2603-2612.
41. Correia NC, Girio A, Antunes I, Martins LR, Barata JT: The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer 2014, 50(1):216-225.
42. Song MS, Salmena L, Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012, 13(5):283-296.
43. Wang Q, Zhou Y, Wang X, Chung DH, Evers BM: Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-kappaB inhibition. Cancer Res 2007, 67(16):7773-7781.
44. Vasudevan KM, Gurumurthy S, Rangnekar VM: Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 2004, 24(3):1007-1021.
45. Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CL: Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res 2013, 73(3):1190-1200.
46. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV: FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res 2010, 70(13):5475-5485.
47. Xu C, Kong X, Wang H, Zhang N, Kong X, Ding X, Li X, Yang Q: MTDH mediates estrogen-independent growth and tamoxifen resistance by down-regulating PTEN in MCF-7 breast cancer cells. Cell Physiol Biochem 2014, 33(5):1557-1567.
48. Tanic N, Milovanovic Z, Tanic N, Dzodic R, Juranic Z, Susnjar S, Plesinac-Karapandzic V, Tatic S, Dramicanin T, Davidovic R, Dimitrijevic B: The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. Cancer Biol Ther 2012, 13(12):1165-1174.
49. Lindberg K, Helguero LA, Omoto Y, Gustafsson JA, Haldosen LA: Estrogen receptor beta represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res 2011, 13(2):R43.
50. Tural D, Serdengecti S, Demirelli F, Ozturk T, Ilvan S, Turna H, Ozguroglu M, Buyukunal E: Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Br J Cancer 2014, 110(12):2996.